Group One Trading
TERN

Group One Trading’s Terns Pharmaceuticals TERN Stock Holding History

Group One Trading’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.38M Buy
64,100
+17,200
+37% +$706K 0.01% 1606
2025
Q4 		$1.89M Buy
46,900
+40,000
+580% +$924K ﹤0.01% 2322
2025
Q3 		$51.8K Sell
6,900
-8,700
-56% -$55.6K ﹤0.01% 5928
2025
Q2 		$58.2K Buy
15,600
+2,000
+15% +$6.25K ﹤0.01% 5451
2025
Q1 		$37.5K Sell
13,600
-18,500
-58% -$75.5K ﹤0.01% 5378
2024
Q4 		$178K Buy
32,100
+5,500
+21% +$37.2K ﹤0.01% 4035
2024
Q3 		$222K Buy
26,600
+20,600
+343% +$169K ﹤0.01% 3518
2024
Q2 		$40.9K Buy
6,000
+4,300
+253% +$26K ﹤0.01% 4672
2024
Q1 		$11.2K Buy
1,700
+500
+42% +$3.27K ﹤0.01% 5813
2023
Q4 		$7.79K Sell
1,200
-1,600
-57% -$8.46K ﹤0.01% 6321
2023
Q3 		$14.1K Sell
2,800
-20,500
-88% -$130K ﹤0.01% 6140
2023
Q2 		$204K Buy
+23,300
New +$272K ﹤0.01% 3911

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Group One Trading's TERN Position: Q1 2026 in Review

Group One Trading sold out of Terns Pharmaceuticals (TERN) in Q1 2026, closing a stake of 70,844 shares — an estimated $2.91M sold.

Group One Trading first reported a position in TERN in Q3 2025 and held it in 2 quarters. The position peaked at $2.86M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Group One Trading reported no remaining Terns Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 70,844 Terns Pharmaceuticals shares in Q1 2026, an estimated $2.91M.
  • Group One Trading first reported a position in Terns Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Group One Trading's Terns Pharmaceuticals position peaked at $2.86M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.